- Home
- FCF vs NVCR Comparison
FCF vs NVCR Comparison
Compare FCF & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FCF
- NVCR
- Stock Information
- Founded
- FCF 1934
- NVCR 2000
- Country
- FCF United States
- NVCR Switzerland
- Employees
- FCF N/A
- NVCR N/A
- Industry
- FCF Major Banks
- NVCR Medical/Dental Instruments
- Sector
- FCF Finance
- NVCR Health Care
- Exchange
- FCF Nasdaq
- NVCR Nasdaq
- Market Cap
- FCF 1.6B
- NVCR 1.9B
- IPO Year
- FCF N/A
- NVCR 2015
- Fundamental
- Price
- FCF $16.24
- NVCR $18.02
- Analyst Decision
- FCF Buy
- NVCR Buy
- Analyst Count
- FCF 8
- NVCR 6
- Target Price
- FCF $18.94
- NVCR $32.83
- AVG Volume (30 Days)
- FCF 520.8K
- NVCR 1.8M
- Earning Date
- FCF 07-22-2025
- NVCR 07-24-2025
- Dividend Yield
- FCF 3.32%
- NVCR N/A
- EPS Growth
- FCF N/A
- NVCR N/A
- EPS
- FCF 1.34
- NVCR N/A
- Revenue
- FCF $448,664,000.00
- NVCR $621,711,000.00
- Revenue This Year
- FCF $14.21
- NVCR $5.56
- Revenue Next Year
- FCF $7.73
- NVCR $9.19
- P/E Ratio
- FCF $12.13
- NVCR N/A
- Revenue Growth
- FCF N/A
- NVCR 18.27
- 52 Week Low
- FCF $13.54
- NVCR $14.17
- 52 Week High
- FCF $19.96
- NVCR $34.13
- Technical
- Relative Strength Index (RSI)
- FCF 61.86
- NVCR 47.07
- Support Level
- FCF $15.77
- NVCR $16.19
- Resistance Level
- FCF $16.22
- NVCR $18.02
- Average True Range (ATR)
- FCF 0.28
- NVCR 0.88
- MACD
- FCF 0.07
- NVCR -0.04
- Stochastic Oscillator
- FCF 97.41
- NVCR 29.74
About FCF First Commonwealth Financial Corporation
First Commonwealth Financial Corp functions in the financial services sector in the United States. Through its subsidiary, it offers a range of consumer and commercial banking services such as personal checking accounts, interest-earning checking accounts, savings accounts, insured money market accounts, investment certificates, fixed & variable rate certificates of deposit, and various kinds of loans. It also provides trust and wealth management services and offers insurance products. The company earns the majority of its revenue through net interest income.
About NVCR NovoCure Limited
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.